A high content clonogenic survival drug screening identifies maytansine as a potent radiosensitizer for meningiomas
PurposeRadiation resistance significantly hinders the efficacy of radiotherapy for meningiomas, posing a primary obstacle. The clinical inadequacy of therapeutic drugs and radiosensitizers for treating meningiomas further exacerbates the challenge. Therefore, the aim of this study was to identify po...
Saved in:
| Main Authors: | Jinxiu Yu, Jiaojiao Deng, Leihao Ren, Lingyang Hua, Tianqi Wu, Yi Hui, Chunlin Shao, Ye Gong |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1557165/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The association between WHO grading and the long-term outcomes and radiotherapy efficacy of intracranial solitary fibrous tumors
by: Leihao Ren, et al.
Published: (2025-08-01) -
Substituted benzylamino-2′-deoxyadenosine a modified nucleoside with radiosensitizing properties
by: Magdalena Datta, et al.
Published: (2025-05-01) -
Discovery of homocamptothecin derivative TOP-0618 as a radiosensitive agent for the treatment of pancreatic cancer
by: Yin Tang, et al.
Published: (2025-05-01) -
The Role of Radiosensitizing Drugs in Osteosarcoma Treatment: Mechanisms and Clinical Perspectives
by: Zhang Y, et al.
Published: (2025-03-01) -
Pitfalls and other issues with the MTT assay
by: David Kessel
Published: (2025-08-01)